Michael Landsittel is CFO at Blueprint Medicines Corp (BPMC). They have made 6 open-market trades across 1 company since 2020, most recently 2025-07-17.
CIK 0001651036
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BPMC | 94,277 | $12.2M |
Shares reported on the most recent Form 4, priced at the 2025-07-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPMC | SELL | 2025-03-05 | 2025-03-07 | $88.80 | $938K | +5.7% | -6.3% | +49.4% |
| BPMC | SELL · 10b5-1 | 2024-08-15 | 2024-08-19 | $95.23 | $840K | -0.6% | -5.1% | -4.2% |
| BPMC | SELL · 10b5-1 | 2024-05-15 | 2024-05-17 | $106.95 | $824K | +1.4% | -1.0% | -8.9% |
| BPMC | SELL · 10b5-1 | 2024-05-02 | 2024-05-06 | $105.00 | $1.1M | +0.6% | -0.2% | -12.3% |
| BPMC | SELL · 10b5-1 | 2024-03-28 | 2024-04-01 | $95.00 | $475K | -2.0% | +0.7% | +15.9% |
| BPMC | SELL · 10b5-1 | 2024-03-15 | 2024-03-19 | $87.78 | $2.4M | +10.7% | +2.0% | +19.2% |
| BPMC | SELL | 2024-03-07 | 2024-03-11 | $90.69 | $907K | +1.0% | +1.5% | +16.7% |
| BPMC | SELL | 2023-03-06 | 2023-03-08 | $45.70 | $270K | +3.2% | -3.4% | +32.1% |
| BPMC | SELL | 2022-03-03 | 2022-03-08 | $58.47 | $278K | +17.5% | +23.4% | +4.6% |
| BPMC | SELL | 2021-03-04 | 2021-03-05 | $86.69 | $253K | +10.7% | +4.9% | -9.4% |
| BPMC | SELL | 2020-03-09 | 2020-03-11 | $51.97 | $21K | +6.0% | +32.0% | +51.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.